Cancer
📧 Sign up to get email alerts when something new happens for Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2013-01-25Clinical Trial Update: Non-invasive Imaging With [18F]VM4-037 [Phase 1]
A Phase 1 clinical trial of the PET imaging agent [18F]VM4-037 was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-01-11Clinical Trial Update: Clonidine for Neurocognitive Sequelae [Phase 1, Phase 2]
The clinical trial investigating clonidine for neurocognitive sequelae associated with cancer treatment has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-01-11Clinical Trial Update: Thiopurine Methyltransferase Polymorphisms Evaluation
A clinical trial evaluating thiopurine methyltransferase polymorphisms in cancer patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-10-19Clinical Trial Update: Study of Curcumin, Vorinostat, and Sorafenib [Phase 1]
A Phase 1 study of curcumin, vorinostat, and sorafenib for advanced cancers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-09-05Clinical Trial Update: A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacokinetics of recombinant human mannose-binding lectin (rhMBL) in pediatric oncolog…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2012-06-22Clinical Trial Update: Intravenous (IV) Lidocaine for Opioid-refractory Pain [Phase 2]
A Phase 2 trial evaluating intravenous lidocaine for opioid-refractory cancer-related pain was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-04-09Clinical Trial Update: The Effects of Aggressive Patient Management on Cancer Therapy Management
A clinical trial evaluating the effects of aggressive patient management on cancer therapy was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-02-24Clinical Trial Update: Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection [NA]
A clinical trial evaluating heparin vs. M-EDTA as catheter lock solutions to prevent infections and blockages in high-risk cancer patients h…
-
EMA withdrawal · 2011-07-20EMA Withdrawn: Filgrastim ratiopharm (filgrastim) — Ratiopharm GmbH
Withdrawn European medicines agency status for filgrastim ratiopharm by Ratiopharm GmbH.
-
CLINICAL_TRIALS withdrawal · 2011-05-16Clinical Trial Update: Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours [Phase 1]
The phase 1 trial of an mTOR kinase inhibitor in advanced solid tumors and lymphomas was withdrawn; no further results are reported.
-
CLINICAL_TRIALS withdrawal · 2011-04-08Clinical Trial Update: Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities [Phase 2]
Phase 2 clinical trial of Newcastle Disease Virus for metastatic cancer patients resistant to conventional therapy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2011-04-08Clinical Trial Update: Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host [Phase 2]
A Phase 2 trial evaluating donor lymphocytes sensitized by host antigens was withdrawn. The sponsor was Hadassah Medical Organization.
-
CLINICAL_TRIALS withdrawal · 2011-01-11Clinical Trial Update: A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team [NA]
The clinical trial evaluating a shared care approach for seriously ill cancer patients between general practice, discharge departments, and …
-
EMA withdrawal · 2010-03-22EMA Application withdrawn: Ratioepo (epoetin theta) — Ratiopharm GmbH
EMA withdrew the application for Ratioepo (epoetin theta) by Ratiopharm GmbH for anemia-related indications.
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Destara (ibandronic acid) — Roche Registration Ltd.
Destara (ibandronic acid) has been withdrawn from the European market by Roche Registration Ltd., affecting indications in hypercalcemia and…
-
EMA withdrawal · 2009-10-13EMA Application withdrawn: Zunrisa (casopitant) — Glaxo Group Ltd
The EMA withdrew the application for Zunrisa (casopitant) from Glaxo Group Ltd for indications in vomiting, postoperative nausea and vomitin…
-
CLINICAL_TRIALS withdrawal · 2009-05-11Clinical Trial Update: A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy [Phase 1, Phase 2]
An early-phase (Phase 1/2) trial of AMG 114 for anemia in cancer patients was terminated.
-
EMA withdrawal · 2009-01-28EMA Withdrawn: Nespo (darbepoetin alfa) — Dompé Biotec S.p.A.
EMA has withdrawn Nespo (darbepoetin alfa) from Dompé Biotec S.p.A.'s portfolio.
-
EMA withdrawal · 2009-01-25EMA Withdrawn: Neupopeg (pegfilgrastim) — Dompé Biotec S.p.A.
EMA withdrawn Neupopeg (pegfilgrastim) by Dompé Biotec S.p.A. indicating the product is no longer active in the market.